| abstract |
A method for treating CLDN18-positive tumors, wherein an antibody that specifically recognizes CLDN18 and chemotherapy drugs are administered to a subject in need thereof. The chemotherapy drugs comprise: 5-fluorouracil, a prodrug thereof, or an active metabolite thereof, and oxaliplatin, a prodrug thereof, or an active metabolite thereof; or 5-fluorouracil, a prodrug thereof, or an active metabolite thereof, oxaliplatin, a prodrug thereof, or an active metabolite thereof, and a taxane drug. A kit combination for treating CLDN18 positive tumors. Compared with the existing technology, the treatment method and the kit combination have greatly enhanced tumor suppression rates and better anti-tumor effects. In addition, the present invention may reduce the use of chemotherapy drugs, and improve the safety of medication and improve tolerance of patients. |